Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
August 24, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Second Quarter Financial Results and Provides Business Update
August 15, 2022 18:03 ET
|
Unicycive Therapeutics, Inc.
On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023 Signed first global...
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
July 26, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...
Unicycive Reports Key Findings from Market Research with Nephrologists
July 20, 2022 07:12 ET
|
Unicycive Therapeutics, Inc.
Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...
Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
July 18, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise Agreement includes upfront payment, royalties...
Unicycive to Present at JMP Securities Life Sciences Conference
June 06, 2022 08:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia
June 02, 2022 08:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today...
Unicycive Announces First Quarter Financial Results and Provides Business Update
May 12, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in second quarter 2022 Plans to initiate Phase 1 study for UNI-494 in second half of...
Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases
April 14, 2022 07:10 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Full Year 2021 Financial Results and Provides Business Update
March 31, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in second half of...